Scilex Holding (SCLXW) Cash from Investing Activities (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Cash from Investing Activities of -$9.2 million in Q1 2026, down 291.47% quarter-over-quarter from $4.8 million in Q4 2025, and down 2218.99% on a YoY basis from $432282.0 in Q1 2025.
Scilex Holding (SCLXW) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Scilex Holding's Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$9.2 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 2218.99% year-over-year to -$9.2 million; the TTM figure through Mar 2026 stood at -$4.7 million (down 60.31% YoY), while the FY2025 annual figure was $4.1 million, up 252.67% from the prior year.
- Cash from Investing Activities was -$9.2 million for Q1 2026 at Scilex Holding, down from $4.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $4.8 million in Q4 2025 to a low of -$9.2 million in Q1 2026.
- Historically, Cash from Investing Activities has averaged -$676533.3 across 5 years, with a median of -$155000.0 in 2023.
- The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities soared 2553.33% in 2025, then plunged 2218.99% in 2026.
- A 5-year view of Cash from Investing Activities shows it stood at -$7000.0 in 2022, then tumbled by 2285.71% to -$167000.0 in 2023, then fell by 16.77% to -$195000.0 in 2024, then jumped by 2553.33% to $4.8 million in 2025, then plunged by 291.47% to -$9.2 million in 2026.
- The last three Cash from Investing Activities figures came in at -$9.2 million (Q1 2026), $4.8 million (Q4 2025), and -$152000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -1.98 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -3.92 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -1.04 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -574.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -10.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -716.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.77 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 785.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -131.00 Mn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -9.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.16 Mn |
| Mar 31, 2026 | -9.16 Mn |
| Dec 31, 2025 | 4.78 Mn |
| Dec 31, 2025 | 4.78 Mn |
| Sep 30, 2025 | -152,000.00 |
| Sep 30, 2025 | -152,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Dec 31, 2024 | -195,000.00 |
| Dec 31, 2024 | -195,000.00 |
| Sep 30, 2024 | -2.18 Mn |
| Sep 30, 2024 | -2.18 Mn |
| Jun 30, 2024 | -150,000.00 |
| Jun 30, 2024 | -150,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Dec 31, 2023 | -167,000.00 |
| Dec 31, 2023 | -167,000.00 |